Schizophrenia/Psychosis

The war experiences of physicians and scientists shaped their research agendas.

A DSM-5 diagnosis requires a biopsychosocial case formulation—not just a symptom checklist.

Aerobic exercise has been found to exert a positive effect on global cognition and some, but not all, cognitive domains in patients with schizophrenia.

What is the long-term, real-world effectiveness of pharmacotherapies for schizoaffective disorder? An investigation into 2 nationwide cohorts of patients living with schizophrenia provides new details.

An antipsychotic changed the life of not only 1 man, but an entire family.

Does switching antipsychotics quell weight gain in patients with severe mental illness? A meta-analysis of 59 relevant studies provides insights.

About 2.4 million people in the US experience dementia related psychosis, yet only half ever receive a diagnosis.

A synthesis of quantitative reviews on the relationship between cannabis use and psychosis.

Data published in The New England Journal of Medicine shows promise for a novel schizophrenia treatment.

The chief medical officer of Karuna shares his thoughts exclusively with Psychiatric Times.

Millions of Americans will suffer brain injuries this year, and many of them will need a psychiatrist’s help.

Is this phase 2 trial the end of the road for a potential new treatment?

Is it possible to use cognitive testing, which is brief, easily performed, reliable, and noninvasive, to identify individuals at risk for psychosis?

How do men versus women with schizophrenia fare clinically, functionally, and neuropsychologically over the long term?

Selfhood: a complex and continuously evolving identity that is anchored in the patient's history and dependent on language and memory. But there is so much more.

Although the clinical symptoms of psychotic disorders are dramatic and are what most clinicians focus on as their treatment targets, impairments in a wide range of cognitive function are observed in these illnesses.

The first-and-only transdermal patch for adults with schizophrenia offers a new treatment.

Be on the lookout for these novel psychoactive substances.

Preliminary studies suggest that adjuvant treatment with a statin may be beneficial for patients who are also prescribed psychotropic drugs for depression and schizophrenia.

In addressing mood disorders associated with infertility, sometimes the cure may be worse than the disease.

How can the best insights of mainstream and critical psychiatry be brought together?

The RISE study results look promising.

There is much to look forward to in the realm of improved treatments for patients with psychiatric illness.

Our basic science knowledge of the brain continues to explode beyond what science fiction of the past has predicted.

Hear details from the phase II trial of xanomeline-trospium and how it assists in the treatment of acute schizophrenia.